JP6466911B2 - Ccl22及びccl17癌生物マーカー - Google Patents
Ccl22及びccl17癌生物マーカー Download PDFInfo
- Publication number
- JP6466911B2 JP6466911B2 JP2016507053A JP2016507053A JP6466911B2 JP 6466911 B2 JP6466911 B2 JP 6466911B2 JP 2016507053 A JP2016507053 A JP 2016507053A JP 2016507053 A JP2016507053 A JP 2016507053A JP 6466911 B2 JP6466911 B2 JP 6466911B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ratio
- ccl17
- ccl22
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7023—(Hyper)proliferation
- G01N2800/7028—Cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
表1は、健康な対照と比較した腎臓の癌患者及び膵臓癌患者の血漿試料におけるCCL17:CCL22比に関して発明者によって生成されるデータを示す。患者群及び正常(対照)群すべては、男性及び女性の被験体を含む。
CCR4 mRNAを腎臓の癌生検におけるリアルタイムRT−PCRによって測定し、及び正常な腎臓と比較した。正常な、及び悪性ヒト腎生検からのmRNAのこの解析は、正常な腎臓試料においてでなく、悪性腎臓におけるCCR4 mRNAの発現を明らかにした(図1)。ヒトの腎臓の癌におけるCCR4発現をさらに調査するために、我々は、免疫組織化学(IHC)を使用してCCR4及びそのリガンドについて腎臓の癌組織マイクロアレイ、TMAを染色した。TMAは、乳頭状の腎臓の癌として分類されたいくつかの生検で、主に明らかな細胞腎癌(75%)からなった。
我々は、48人のRCC患者からの血漿におけるCCR4リガンドCCL17及びCCL22のレベルを測定し、及びこれらを年齢がマッチした個体からの26の正常な血漿試料と比較した。CCL22及びCCL17血漿レベルは、製造業者の説明書に従ってヒト炎症性ケモカインK15001C−2についてMeso Scale Discovery(商標)(MSD)システム多重アッセイを利用して決定した。
血漿CCL17:CCL22の比が腎臓の癌における診断及び予後の生物マーカーであることを確立して、我々は、また、この関係がその他の癌型において存在するかどうかを調査した。我々は、膵臓癌及び卵巣癌(高悪性度の漿液の卵巣癌、HGS)を分析し、及びまた、これらの癌において血漿CCL17:CCL22の比が統計的に有意な癌マーカーであることを確認した(図9及び10)。表1及び2は、この研究及びその解析の部分として生成されるデータを示す。
我々は、CCR4に拮抗性の完全ヒトIgG1抗体(Affi−5を意味する、Affitech Research AS, Gaustadalleen 21, N−0349, Oslo, Norwayから得られる)がTranswell(登録商標)遊走アッセイにおけるCCL17への768−O及びA498細胞の遊走を阻害することを決定した。簡潔には、786−OまたはRENCA細胞をEDTAに基づいた緩衝液で収集し、培地(786−Oについては無血清、RENCAについては0.5%の血清を含む)において再懸濁して、45分間Affi−5または対照IgGとプレインキュベートした。1−2×105細胞をTranswell(登録商標)インサート(12−ウェルフォーマット)の上部に播いて、ヒトCCL17(Peprotech)またはマウスCCL17(R&D、1−001−A)の示した濃度を含む培地を底面スペースに添加した。一晩のインキュベーション後、Transwell(登録商標)インサートを綿棒でインサートの上部に残っている細胞を除去した後に修飾されたGIEMSA染色で染色した。膜をインサートから切除し、及びスライド上に乗せた。インサート当たりの10のフィールドにおける細胞数は、40×倍率で顕微鏡にて計数した。それぞれの条件について三通りを解析した。マウスCCL17へのRENCA細胞の遊走が阻害され、また抗体がマウスCCR4に拮抗性であったことを示している。
実施例4において記述される1つに同等の研究をCCR4、図14において示される化学的式を有するAZD2098を意味する化合物の化学的アンタゴニストを使用することによって実施した。
Claims (7)
- (i)癌の進行または発症をモニターすること;
(ii)治療に対する癌の応答をモニターすること;
(iii)癌を診断すること;
(iv)癌予後;及び/または
(v)癌が治療に応答する可能性を予測すること
に関連した情報を得るための方法であって、前記方法は、被験体からの試料において循環しているCCL17と循環しているCCL22との比を決定することを含む、前記方法であって、
前記方法は、前記CCL17:CCL22比を対照または参照比と比較することを含み、前記試料は、血液、血漿、または血清であり、癌が腎臓癌、膵臓癌、および卵巣癌から選択され、
(i)前記被験体における増大したCCL17:CCL22比は、癌の発症または進行の可能性が高いことを示す;
(ii)前記被験体における減少したCCL17:CCL22比は、前記治療に応答した前記癌の可能性が高いことを示す;
(iii)前記被験体における増大したCCL17:CCL22比は、前記被験体が癌を有する可能性が高いことを示す;
(iv)前記被験体における増大したCCL17:CCL22比は、有害な予後の可能性が高いことを示す;および/または
(v)前記被験体における増大したCCL17:CCL22比は、癌が治療に応答する可能性が高いことを示す、前記方法。 - 請求項1に記載の方法であって、前記方法は、循環しているCCL17及び循環しているCCL22のレベルを決定すること、及びCCL17:CCL22比を算出することを含む、前記方法。
- 前記方法は、抗体を使用してCCL17及びCCL22のレベルを決定することを含む、請求項2に記載の前記方法。
- 請求項1〜3のいずれかに記載の方法であって、前記試料は、血清または血漿である、前記方法。
- 請求項1〜4のいずれかに記載の方法であって、前記癌は、腎臓癌である、前記方法。
- 請求項1〜4のいずれかに記載の方法であって、前記癌は、卵巣癌である、前記方法。
- 請求項1〜4のいずれかに記載の方法であって、前記癌は、膵臓癌である、前記方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1306394.6 | 2013-04-09 | ||
GB1306394.6A GB2512857A (en) | 2013-04-09 | 2013-04-09 | Cancer biomarker |
PCT/GB2014/051096 WO2014167316A1 (en) | 2013-04-09 | 2014-04-09 | Ccl22 and ccl17 cancer biomarkers |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016516209A JP2016516209A (ja) | 2016-06-02 |
JP6466911B2 true JP6466911B2 (ja) | 2019-02-06 |
Family
ID=48483593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016507053A Expired - Fee Related JP6466911B2 (ja) | 2013-04-09 | 2014-04-09 | Ccl22及びccl17癌生物マーカー |
Country Status (7)
Country | Link |
---|---|
US (1) | US10241118B2 (ja) |
EP (1) | EP2984486A1 (ja) |
JP (1) | JP6466911B2 (ja) |
AU (1) | AU2014252894A1 (ja) |
CA (1) | CA2908908A1 (ja) |
GB (1) | GB2512857A (ja) |
WO (1) | WO2014167316A1 (ja) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050220787A1 (en) * | 2002-11-07 | 2005-10-06 | Lobo Peter I | Naturally occuring IgM antibodies that bind to lymphocytes |
US6488930B1 (en) * | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
US7144903B2 (en) | 2001-05-23 | 2006-12-05 | Amgen Inc. | CCR4 antagonists |
SE0301650D0 (sv) | 2003-06-04 | 2003-06-04 | Astrazeneca Ab | Novel compounds |
US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
EP2091551B1 (en) * | 2006-11-03 | 2020-01-15 | Alba Therapeutics Corporation | Method of treating asthma |
GB0717637D0 (en) * | 2007-09-10 | 2007-10-17 | Univ Leiden | Future cardiac event biomarkers |
GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
AU2011265258A1 (en) * | 2010-06-11 | 2013-01-10 | Calistoga Pharmaceuticals, Inc. | Methods of treating hematological disorders with quinazolinone compounds in selected patients |
GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
-
2013
- 2013-04-09 GB GB1306394.6A patent/GB2512857A/en not_active Withdrawn
-
2014
- 2014-04-09 EP EP14721927.3A patent/EP2984486A1/en not_active Withdrawn
- 2014-04-09 US US14/782,929 patent/US10241118B2/en not_active Expired - Fee Related
- 2014-04-09 CA CA2908908A patent/CA2908908A1/en not_active Abandoned
- 2014-04-09 AU AU2014252894A patent/AU2014252894A1/en not_active Abandoned
- 2014-04-09 WO PCT/GB2014/051096 patent/WO2014167316A1/en active Application Filing
- 2014-04-09 JP JP2016507053A patent/JP6466911B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2908908A1 (en) | 2014-10-16 |
AU2014252894A1 (en) | 2015-10-29 |
EP2984486A1 (en) | 2016-02-17 |
US20160041187A1 (en) | 2016-02-11 |
WO2014167316A1 (en) | 2014-10-16 |
US10241118B2 (en) | 2019-03-26 |
GB2512857A (en) | 2014-10-15 |
JP2016516209A (ja) | 2016-06-02 |
GB201306394D0 (en) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yamauchi et al. | Circulating and tumor myeloid-derived suppressor cells in resectable non–small cell lung cancer | |
RU2558931C2 (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
JP2012526544A5 (ja) | ||
US20170030912A1 (en) | S100p and hyaluronic acid as biomarkers for metastatic breast cancer | |
Tokumaru et al. | Lymphocyte-to-monocyte ratio is a predictive biomarker of response to treatment with nivolumab for gastric cancer | |
JP2012526543A5 (ja) | ||
JPWO2019117132A1 (ja) | がん免疫療法の予後予測のためのバイオマーカー | |
US9557333B2 (en) | Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level | |
JP2013213774A (ja) | 結核検査用バイオマーカー | |
JP6466911B2 (ja) | Ccl22及びccl17癌生物マーカー | |
EP3215851A2 (en) | Lung cancer sub-typing method | |
Rupp et al. | Lack of clinical utility of serum macrophage migration inhibitory factor (MIF) for monitoring therapy response and estimating prognosis in advanced lung cancer | |
Kozak et al. | Utility of different serum fibrosis markers in diagnosing patients with chronic pancreatitis and pancreatic adenocarcinoma | |
DK2831590T3 (en) | NEW MOLECULAR LUNG CANCER MARKERS | |
JP2019518970A (ja) | 腎臓癌を患う対象の癌治療に対する感受性を予測するための方法およびキット | |
EP2895863B1 (en) | New biomarkers for the diagnosis and/or prognosis of clear cell renal cell carcinoma | |
KR102599695B1 (ko) | 마커 사람 부고환 단백질 4 (he4) 기반의 폐 선암 재발의 발견 방법 및 관련 용도 | |
Mohammed | Determination of Serum IL-8 Level in Women with Breast Cancer and Their Correlation With Disease Progression | |
WO2023234422A1 (ja) | 三次リンパ組織の検査方法、及び三次リンパ組織の検査用キット | |
KR102644839B1 (ko) | 종양 관련 호중구를 이용한 위암의 예후 예측 방법 | |
KR102357465B1 (ko) | 혈액 종양에서의 ngal 및 vegf | |
EP3570028A1 (en) | Assessing responsiveness of rheumatoid arthritis patients to biological treatment | |
Lim et al. | Quantitative Peripheral Live Single T-Cell Dynamic Polyfunctionality as a Predictive Biomarker in Cancer Immunotherapy | |
Roblin et al. | P135 Association of Serum Anti-Muscarinic 3 Antibodies with Gastrointestinal Disease in Systemic Sclerosis | |
US20100120080A1 (en) | Cancer diagnosis using ki-67 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170331 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20180124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180206 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180423 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180704 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181218 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6466911 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |